Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
of the first-in-human Phase I trial of its investigational antibody drug conjugate (ADC) DS-9606 for treating advanced solid tumours. Developed in collaboration with the Tokyo University of Pharmacy and Life Sciences, DS-9606 is designed using Daiichi Sankyo's second ADC technology platform. The drug comprises a humanised Claudin-6 (CLDN6) monoclonal antibody linked to a modified PBD payload. The latest findings indicated promising clinical activity in patients with advanced solid tumors expressing CLDN6. DS-9606, a modified pyrrolobenzodiazepine (PBD) ADC, targets CLDN6, a protein found in several tumour types, including endometrial, ovarian, and gastric cancers, germ cell tumours, and non-small cell lung cancer. The Phase I trial involved 53 heavily pretreated patients with various cancers. These patients had already undergone a median of four prior therapies. The safety and tolerability of DS-9606 were assessed across doses ranging from 0.016 mg/kg to 0.225 mg/kg. No do
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Metastatic Triple-Negative Breast Cancer (mTNBC) Pipeline Landscape Research 2024: Comprehensive Insights About 10+ Companies and 12+ Drugs [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOSBusiness Wire
- Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerBusiness Wire
- Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ TechnologyPR Newswire
- ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology ProductBusiness Wire